Yet, a great promise for improved cancer therapy lies in dual inhibitors of p53/MDM2 and p53/MDM4 (without inhibitors), such as α-helical p53 stapled peptidomimetic ALRN-6924, which is in phase I/II clinical development (Saleh et al., 2021). This evidence concerns the gene MDM4 and cancer.